Lipitor vs Lisinopril: Head-to-Head Efficacy for Cardiometabolic Risk

What each drug is actually for

Atorvastatin blocks HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis; in animal models the liver responds by raising the number of LDL receptors, which pulls more LDL out of the bloodstream [4]. Lisinopril blocks angiotensin-converting enzyme, so less angiotensin II is produced; lower angiotensin II means less vasoconstriction and less aldosterone, which can raise serum potassium slightly [5].

The Lipitor label's indications all concern lipids and atherosclerotic risk: reducing MI, stroke, revascularization and angina in adults with multiple CHD risk factors but no evident CHD; reducing MI and stroke in adults with type 2 diabetes and multiple risk factors; reducing events in adults who already have CHD; and lowering LDL-C in primary hyperlipidemia and familial hypercholesterolemia [4]. The Zestril label lists three indications: hypertension in adults and children 6 years and older, systolic heart failure, and reducing mortality in hemodynamically stable patients within 24 hours of an acute myocardial infarction [5].

Lisinopril's outcome evidence sits in those same settings: hypertension (ALLHAT) [2], heart failure (ATLAS) [6], and the first 24 hours after an acute myocardial infarction (GISSI-3) [3]. The Lipitor label has no blood-pressure indication [4].

What the two large trials actually tested

Two large trials each tested one of the drugs in high-risk hypertensive patients, and they answer different questions [1][2].

ASCOT-LLA took 10,305 patients from a hypertensive trial population — aged 40 to 79, at least three other cardiovascular risk factors, non-fatal total cholesterol 6.5 mmol/L or less — and added atorvastatin 10 mg or placebo. Treatment stopped at a median 3.3 years: 100 primary events (non-fatal MI plus fatal CHD) on atorvastatin versus 154 on placebo, HR 0.64 (95% CI 0.50 to 0.83, p=0.0005). Fatal and non-fatal stroke fell from 121 to 89 (HR 0.73, 95% CI 0.56 to 0.96) and total coronary events from 247 to 178 (HR 0.71) [1]. Everyone in that trial was already enrolled in a blood-pressure trial, so the result is about adding a statin on top of blood-pressure treatment.

ALLHAT randomized 33,357 hypertensive adults aged 55 or older with at least one other CHD risk factor to chlorthalidone (n=15,255), amlodipine (n=9,048) or lisinopril 10 to 40 mg (n=9,054). On the primary outcome of fatal CHD or nonfatal MI, lisinopril matched the diuretic: RR 0.99 (95% CI 0.91 to 1.08). All-cause mortality did not differ, and 5-year systolic pressure was 2 mmHg higher on lisinopril than on chlorthalidone (P<.001) [2]. ALLHAT compared lisinopril with a diuretic, not with a statin.

Atorvastatin's outcome data, by population

• LDL-C by dose. Pooled 6-week data in primary hyperlipidemia show mean LDL-C changes of minus 39% at 10 mg, minus 43% at 20 mg, minus 50% at 40 mg and minus 60% at 80 mg, against a 4% rise on placebo [4].
• Type 2 diabetes without cardiovascular disease (CARDS). 2,838 patients, atorvastatin 10 mg versus placebo, stopped early for efficacy at a median 3.9 years. Major cardiovascular events 83 versus 127, a 37% rate reduction (p=0.001) [7].
• Stable CHD (TNT). 10,001 patients, atorvastatin 80 mg versus 10 mg, median 4.9 years. Mean on-treatment LDL-C 77 versus 101 mg/dL; major cardiovascular events 434 (8.7%) versus 548 (10.9%), HR 0.78 (95% CI 0.69 to 0.89); overall mortality did not differ [8].
• Recent stroke or TIA (SPARCL). 4,731 patients, atorvastatin 80 mg versus placebo, median 4.9 years. Fatal or non-fatal stroke 265 (11.2%) versus 311 (13.1%), HR 0.84 (95% CI 0.71 to 0.99). Ischemic strokes were fewer (218 versus 274) but hemorrhagic strokes were more frequent (55 versus 33) [9].

Lisinopril's outcome data, by setting

• After acute MI (GISSI-3). 19,394 patients randomized within 24 hours, lisinopril 5 mg then 10 mg daily for six weeks against open control. Six-week mortality was 6.7% overall, and lisinopril reduced mortality (odds ratio 0.88, 95% CI 0.79 to 0.99) [3].
• Heart failure (ATLAS). 3,164 patients with NYHA class II to IV symptoms and ejection fraction 30% or less, low-dose lisinopril 2.5 to 5 mg (n=1,596) versus high dose 32.5 to 35 mg (n=1,568) for 39 to 58 months. Death was 8% lower on the high dose, which was not significant (P=0.128); death or any hospitalization was 12% lower and heart-failure hospitalization 24% lower [6].
• Adding lisinopril to an ARB (VA NEPHRON-D). 1,448 patients with type 2 diabetes and albuminuria already taking losartan 100 mg were randomized to lisinopril 10 to 40 mg or placebo, and the trial stopped early for safety. The primary kidney endpoint did not improve (HR 0.88, 95% CI 0.70 to 1.12), while hyperkalemia (6.3 versus 2.6 events per 100 person-years) and acute kidney injury (12.2 versus 6.7) were more frequent with the combination [10].

Side effects: what the data report

Atorvastatin. Across 17 placebo-controlled trials (8,755 on atorvastatin, 7,311 on placebo, median 53 weeks), myalgia was reported by 3.5% versus 3.1%, muscle spasms by 3.6% versus 3.0%, and arthralgia by 6.9% versus 6.5%. Discontinuations above placebo were myalgia 0.7%, diarrhea 0.5%, nausea 0.4%, and ALT or hepatic enzyme increase 0.4% each [4]. Persistent transaminase rises above three times the upper limit of normal occurred in about 0.7% of patients overall, and by dose in 0.2% at 10 mg, 0.2% at 20 mg, 0.6% at 40 mg and 2.3% at 80 mg [4]. HbA1c and fasting glucose can rise [4]. The label also flags hemorrhagic stroke with 80 mg: in a post-hoc SPARCL analysis of the 80 mg group, hemorrhagic stroke occurred in 2.3% on atorvastatin versus 1.4% on placebo (HR 1.68, 95% CI 1.09 to 2.59), and among patients who entered the trial with a hemorrhagic stroke the figures were 16% versus 4% [4].

Lisinopril. The Zestril label says angioedema of the face, lips, tongue, glottis or larynx, including some fatal reactions, can occur at any time during treatment, with a higher rate in Black than in non-Black patients. It also carries a boxed fetal-toxicity warning [5]. The label lists hyperkalemia as a risk, particularly with renal insufficiency, diabetes, potassium-sparing diuretics, potassium supplements and potassium-containing salt substitutes [5]. In ATLAS, dizziness and renal insufficiency were more frequent on high-dose lisinopril (32.5 to 35 mg daily) than on the low dose (2.5 to 5 mg) [6]. The VA NEPHRON-D hyperkalemia and acute kidney injury rates (above) describe lisinopril added to losartan, not lisinopril alone [10]. For a sense of ACE-inhibitor angioedema rates in a large trial, OCTAVE enrolled 25,302 patients with hypertension: angioedema occurred in 0.68% of those on enalapril, a different ACE inhibitor, versus 2.17% on omapatrilat [11].

The boxed warning says to discontinue lisinopril as soon as pregnancy is detected [5]. First-trimester observational studies disagree about whether ACE-inhibitor exposure itself raises malformation risk. A Tennessee Medicaid cohort of 29,507 infants found a higher risk of major congenital malformations with first-trimester-only ACE-inhibitor exposure (risk ratio 2.71, 95% CI 1.72 to 4.27) [12]. A Kaiser Permanente cohort of 465,754 mother-infant pairs found congenital heart defects in 3.9% of first-trimester ACE-inhibitor pregnancies versus 1.6% of unexposed pregnancies (odds ratio 1.54, 95% CI 0.90 to 2.62); the rate was 2.4% among women with hypertension who took no antihypertensive [13].

Interaction warnings in each label

Atorvastatin is a CYP3A4 and transporter substrate, so its interaction warnings centre on drugs that raise its exposure. The Lipitor label caps the dose at 20 mg daily with clarithromycin or itraconazole, at 40 mg with nelfinavir, and does not recommend it at all with cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir. It advises avoiding large quantities of grapefruit juice, more than 1.2 liters daily [4].

The Zestril label's interaction warnings concern potassium-raising agents, diuretics (excessive blood pressure reduction when lisinopril is started), NSAIDs (possible worsening of kidney function and a weaker antihypertensive effect), lithium, and dual blockade of the renin-angiotensin system with ARBs or aliskiren. Sacubitril is contraindicated [5]. In VA NEPHRON-D, adding lisinopril to an ARB gave no kidney benefit and more hyperkalemia and acute kidney injury [10].

Kidney function separates the two drugs. Atorvastatin needs no renal dose adjustment, and renal disease does not change its concentrations or its LDL-C effect; renal impairment is still listed as a myopathy risk factor [4]. Lisinopril is not metabolized and is excreted unchanged in the urine; the Zestril label halves the usual initial dose at a creatinine clearance of 10 to 30 mL/min [5].